Someone else’s problem
Every chemist knows the feeling. A molecule that should be easy is not. A reaction that works on a gram fails on a kilogram. A drug candidate is too insoluble, too unstable, too quickly destroyed by the liver. In a university, such problems can wait. In a company, they cannot. Somewhere a patient is waiting too.
For most of the twentieth century, the two worlds kept a polite distance. Companies wrote large, unrestricted checks to universities in exchange for first access to whatever came out the other end: blanket agreements and first-rights deals. It was generous, and it was blunt. Academic and industrial interests were not always aligned, and as the economics of drug discovery tightened, those grants grew harder to justify and rarer to find.
What replaced them was smaller, sharper and, in our experience, far better. In 2015, Quentin Michaudel, Yoshihiro Ishihara and Phil Baran set down what the lab had learned in an Accounts of Chemical Research article with a deliberately biological title: Academia–Industry Symbiosis in Organic Chemistry. A company brings a precise, urgent problem that it has neither the time nor the mandate to solve from first principles. An academic lab brings the freedom to do exactly that. Each partner keeps the other alive.
“In our view, forging a partnership with industry can be a golden opportunity for both parties and can represent a true symbiosis.”
By the time that Account was written, more than a dozen projects had grown out of such partnerships. A decade later the number is 110. Roughly 42% of everything this laboratory has published carries the name of at least one industrial scientist.
A leap of faith
The first partnership began with a creature from the sea and a question nobody could answer.
Haouamine A, a contorted heptacyclic alkaloid from a marine tunicate, showed tantalizing signs of activity against cancer cells. But the animal yields only traces, far too little for the careful biology a company like Genentech needs. The lab had already made haouamine once; that route, built to prove a point, could not make much of it. Prompted by Rami Hannoush at Genentech, the group went back to the drawing board. A third-generation route made more than 15 grams of a key intermediate and closed with a chirality-transfer endgame, delivering haouamine A and its atropisomer in quantity. With material in hand, Genentech showed that both forms are active against PC3 prostate cancer cells and that the strained cyclophane ring is essential. The work appeared in JACS in 2009, the lab’s first paper with an industrial co-author. An academic ambition, a scalable synthesis of a ferociously complex molecule, had become an industrial purpose.
Two years later came a bolder bet. LEO Pharma, a Danish company devoted to skin disease, had only ever worked with contract research organizations. In 2011 it chose instead to partner with an academic group, with no guarantee that the group could deliver. The target was ingenol, the core of LEO’s drug Picato, a molecule whose strained in,out ring system had defeated every attempt at a short synthesis; the existing routes ran to more than 35 steps.
Two-phase terpene logic, building the carbon skeleton first and then installing oxidation the way nature does, delivered ingenol in 14 steps from (+)-3-carene. Through biweekly teleconferences and a constant stream of email, Jakob Felding’s team at LEO guided which analogs would matter and helped steer the chemistry. The leap of faith became a lasting relationship: ouabagenin and hydroxylated corticosteroids, a 19-step synthesis of phorbol, scalable thapsigargin, chemical proteomics that identified a target of the ingenol drug class, a convergent synthesis of the psoriasis drug calcipotriol and a convergent total synthesis of cyclopamine.
Patience and optimism
In 2012, Scripps and Bristol Myers Squibb entered a long-term, multi-laboratory partnership. Because both medicinal chemists and process chemists came to the table, the problems ranged from the first milligram of a lead compound to the last kilogram of a drug candidate.
The first joint project took two famous triterpenes, betulin and betulinic acid, with promising anti-HIV, anti-inflammatory and anticancer activity and almost no solubility in water. Combining chemical and enzymatic C–H oxidation, the lab made eight oxidized derivatives; BMS measured them and found dramatic gains in solubility. Alicia Regueiro-Ren orchestrated the exchange of data and molecules across several BMS groups. With BMS process chemists Martin Eastgate and Ke Chen, the lab then built on an in-house BMS observation to create a mild, regioselective bromination of fused pyridine N-oxides; by 2015 BMS was using it to make kilogram quantities of a drug candidate.
Not every project ran smoothly. A radical C–H imidation of arenes took a year and a half, and on many occasions came close to being abandoned. The Account credits its survival to one person: “it was the patience and optimism from our BMS colleague that paved the way to fruition.” That colleague, Martin Eastgate, has since co-authored more than twenty papers with the lab. The same years produced Palau’chlor, a guanidine-based chlorinating reagent named for the natural product palau’amine, whose stability and large-scale safety were assessed with the help of BMS process chemistry.
What followed is one of the most productive academic–industrial relationships in modern synthesis: scalable, sustainable electrochemical allylic C–H oxidation, redox-active esters for alkyl–alkyl cross-coupling, decarboxylative alkenylation, P(V) reagents for chiral phosphorothioates and a P(V) platform for oligonucleotide synthesis, complex-molecule synthesis by electrocatalytic decarboxylative cross-coupling, and sulfonyl hydrazides as a general platform for radical cross-coupling. Medicinal chemists, process chemists, radiochemists and discovery scientists from BMS have co-authored 52 papers with the lab, more than any other company.
Every few weeks, in person
Pfizer’s story traces the shift the Account describes. From 2007 to 2011, Scripps and Pfizer ran a five-year, first-rights research collaboration. When it ended, Pfizer chose something more intimate: focused partnerships with individual laboratories, including ours.
The new arrangement was simple. The lab gained access to compounds from confidential Pfizer projects for internal scientific use; Pfizer scientists saw unpublished results and could put them to work at once. It began with a new reagent for direct difluoromethylation. The lab had set out to make a sodium salt and could not; what crystallized instead, zinc difluoromethanesulfinate (DFMS), turned out to be better. Michael Collins of Pfizer has been at the lab’s side ever since, bringing “the valuable perspective of a practicing medicinal chemist.” Pfizer’s La Jolla site sits close to Scripps, both figuratively and geographically, and the two groups met in person every few weeks to trade ideas and molecules.
The sulfinates became a general toolkit for innate C–H functionalization of heterocycles (with a protocol for making them). When a 2013 review issued a call for new C–H methylation reactions, Collins, Aaron Burns and Martha Ornelas at Pfizer answered it with the lab, inventing a two-step heteroarene methylation designed so that the product is easy to purify. When another paper made the case for trifluoromethylcyclopropyl groups as metabolically stable stand-ins for tert-butyl, a sulfinate that installs them followed. And when Pfizer needed a quick way to predict which heteroarenes the enzyme aldehyde oxidase would attack, DFMS became a simple litmus test: react at room temperature, look for a peak 50 mass units heavier, and you know where the liver will strike.
“Our industrial partners can often identify “real-world” problems better than we can, owing to their years of experience in multidisciplinary research targeting diseases.”
The partnership never slowed. Strain-release amination gave medicinal chemists the small, strained rings they prize. Radical cross-coupling with sulfones delivered sp3-rich fluorinated scaffolds. Electroreduction inspired by lithium-ion batteries made dissolving-metal chemistry safe. Carbon quaternization, sulfonyl hydrazides and, in 2026, stereoretentive radical alkyl–alkyl cross-coupling followed. Pfizer scientists are co-authors on 30 of the lab’s papers; Michael Collins alone is on 22.
From the bench to the bottle
A reaction that only its inventors can run is a curiosity. The lab learned early that new chemistry reaches the clinic only if the reagents are in a catalog.
Industrial chemists, the Account observes, work under time pressure that rules out making most reagents themselves; they adopt a method when they can buy what it needs. So when DFMS and its trifluoromethyl cousin TFMS were published, they went straight to Sigma-Aldrich, and their sales passed $100,000 in under eighteen months. In 2013 Scripps and Sigma-Aldrich formalized the arrangement as a multi-investigator partnership: the lab shared unpublished work every two weeks, Sigma-Aldrich supplied raw materials and sped commercialization. By 2015 dozens of the lab’s reagents could be ordered from a catalog. The same conviction later led the lab to co-develop standardized electrochemistry hardware with IKA, whose scientists appear on the 2021 paper introducing rapid alternating polarity.
Other partners took the reagents somewhere no one expected. Morphotek, an Eisai company building antibody–drug conjugates, wanted to attach drugs that offer no obvious handle, only C–H bonds. The answer was native chemical tagging: a sulfinate reagent carrying an azide that tags such molecules directly, ready to be clicked onto an antibody. Eisai chemists have since joined the lab on a strategy for building C(sp3)-rich complexity and electrochemical C(sp3)–H fluorination.
The terms of a symbiosis
Symbiosis is not charity in either direction. The Account closed with a short table of what each partner owes the other, and it still reads like a contract worth signing. Hover over, or tap, either column to see how each obligation is answered.
- Out-of-the-box solutions “Real-world” problems
- Education of students Multidisciplinary expertise
- Biweekly progress Biweekly phone conference or meeting
- Quarterly or annual summary and future ideas Quarterly or annual assessment and future goals
- Meeting deadlines Patience when facing challenges
- Sharing discoveries through publications Filing patents
- Discovering new science Applying collaborative science
Table 1, “General Expectations in a Fruitful Academia–Industry Symbiosis,” Acc. Chem. Res. 2015, 48, 712.
The rhythm matters as much as the terms: biweekly calls to keep momentum, quarterly or annual meetings to lift everyone’s eyes to the larger goal, clear deliverables and deadlines, and early agreement on intellectual property. Above all, the Account insists, “both sides must be driven by the will to discover new science.” Not every problem suits such a partnership. Many can be shaped to fit.
The best classroom
The deepest benefit of these partnerships does not appear in any table of yields. It walks out of the lab at graduation.
A graduate student on an industrial project learns things no course can teach. Why a medicinal chemist cares more about solubility than elegance. Why a process chemist asks whether a reagent is safe at scale before asking whether it is clever. How to present unfinished results to scientists who have shipped medicines, defend a hypothesis on a biweekly call, and hear, with good grace, that the beautiful reaction fails on the compound that matters. The Account calls this “a unique opportunity for students to face challenges from the ‘real world’ at an early stage of their career,” and it names the bargain plainly: academia owes its students specialized scientific education, and industry complements it with multidisciplinary expertise no single university lab can match.
The mentors are extraordinary. Over the years our students and postdocs have learned from 259 industrial co-authors: process chemists who have scaled drugs to market, medicinal chemists who have taken candidates into the clinic, analytical, radiochemistry, biology and engineering teams who taught them to see a molecule through other eyes. Industry has also invested in trainees directly; the Account itself acknowledges a Bristol-Myers Squibb graduate fellowship that supported its first author.
And then the circle closes. Students trained on these projects go on to industry themselves, and some come back, now as the industrial co-authors. Their names appear on the lab’s papers twice: once as students, and again as partners.
A wider circle
What began as one company and one alkaloid is now a network of 26 companies on three continents: global pharmaceutical leaders, biotechnology pioneers, agrochemical innovators, contract research and manufacturing organizations, building-block suppliers and technology makers.
Increasingly, they sit at the same table. A 2022 paper on Ag–Ni electrocatalytic decarboxylative arylation carries co-authors from six companies. A 2023 Nature paper on electrocatalytic cross-coupling for complex molecules and a 2026 Nature Chemistry paper on triply convergent assembly of cyclobutanes, azetidines and oxetanes each carry five. Competitors in the market become colleagues in the literature, because a better reaction helps every patient. 38 of the lab’s industry papers involve more than one company.
The range is breathtaking. Merck and Debut Biotechnology joined a scalable total synthesis of saxitoxin. Chemveda Life Sciences helped bring the two-phase synthesis of Taxol to life. AbbVie process chemists turned waveform-controlled electrosynthesis against the long-standing limits of the Kolbe reaction. Elsie Biotechnologies, now part of GSK, carried P(V) oligonucleotide chemistry toward medicine. Enamine, Biogen, Asymchem, Minakem, Syngenta, Vividion and many others have each left their mark. Every partner is listed below, with every paper we have written together.
Drawn from Academia–Industry Symbiosis in Organic Chemistry, Quentin Michaudel, Yoshihiro Ishihara and Phil S. Baran, Acc. Chem. Res. 2015, 48, 712–721, and from the papers themselves.

















